News

A multicenter trial of the CAR T-cell product MB-106 has treated its first patient, Mustang Bio, Inc announced.

In the interview with Targeted Oncology, Anna Jo Bodurtha Smith, MD, discusses the effects various insurance types have on the quality of care of patients with gynecologic cancers.

A survival benefit was elicited with the use of pemigatinib when used for patients with previously treated advanced cholangiocarcinoma who had an FGFR2 fusion or rearrangement.

As part of the phase 2 INSIGhT trial, VBI Vaccines, Inc, and Agenus will examine the combination of VBI-1901 and balstilimab in patients with glioblastoma.

The first of 160 patients with gastric or gastroesophageal junction cancer has been recruited for the phase 2 DisTinGuish study. Thirty-two study locations are actively recruiting more patients.

Three different sequencing schemas for immunotherapy followed by targeted therapy in patients with BRAF V600-mutant melanoma have shown positive survival outcomes and safety consistent with results from prior studies.

The PRESERVE 2 trial evaluating trilaciclib in patients with metastatic breast cancer has finished enrolling patients. Results from the interim analysis of the trial is expected in the second half of 2023.

Considering the potential to fill a treatment gap in the KRAS G12C-mutant non–small cell lung cancer population, the FDA has granted a fast track designation to the combination of BBP-398 and sotorasib.

In an interview with Targeted Oncology, Hagop Kantarjian, MD, analyzed the results of the phase 2, OPTIC and PACE trials and explained what these data mean for the future use and administration of ponatinib.

In an interview with Targeted Oncology, Kjeld Schmiegelow, MD provided a deep dive into his SOHO 2022 presentation as well as the other acute lymphoblastic leukemia discussions presented during the session.

Data from the DREAMseq trial have answered a lingering question of how to sequence therapy for patients with advanced BRAF-mutant melanoma. This research supports immunotherapy in the first-line setting, followed by BRAK/MEK inhibitors.

Twelve-week safety data from the phase 2 ENVASARC trial of envafolimab alone and in combination with ipilimumab in patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma support proceeding with enrollment of patients in the trial.

Phase 1 results examining azacitidine and venetoclax in high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia elicited an overall response rate of 87%.

Matthew P. Goetz, MD, discusses recent data on estrogen receptor mutations in patients with breast cancer.

The phase 1/2 clinical trial of MB-106 is demonstrating high efficacy, durable responses, and a favorable safety profile as the first patient treated did not experience cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome

More interventions are needed to address fatigue in survivors of cancer and hematopoietic stem cell transplant.

In an interview with Targeted Oncology, Ronan Kelly, MD, discussed the most recent updates seen in these patient populations and what research aims to further examine.

Following positive data examining ABC008 for inclusion body myositis, a phase 1/2 trial has begun evaluating the agent in patients with T-cell large granular lymphocytic leukemia.

Findings from the phase 1b/2a trial evaluating a universal cancer peptide-based vaccine at a 3-dose schedule in patients with metastatic non–small cell lung cancer showed the vaccine to be safe and effective.

There have been marked improvements in expected remission and overall survival rates in mantle cell lymphoma even though a cure for this disease remains elusive.

In an interview with Targeted Oncology, Ghassan K. Abou-Alfa, MD, discussed 3 late breaking abstracts in the hepatocellular carcinoma space currently influencing the field.

Exelixis, Inc has expanded their clinical trial collaboration and supply agreement with Bristol-Myers Squibb to evaluate the novel triplet of nivolumab, relatlimab, and XL092 in the phase 1b STELLAR-002 trial.

Paul G. Richardson, MD, discusses what is expected and exciting for the future of multiple myeloma research.

Early results from the phase 2a MYLOX-1 study show a reduction of collagen fibrosis of the bone marrow in patients with myelofibrosis on the LOXL2 inhibitor GB2064.

Analysis from the phase 3 CALGB/SWOG-80405 trial reveals that acquired genomic alterations in patients treated with cetuximab in combination with chemotherapy in the first-line were not common.

Findings from the PERLA trial examining the combination of dostarlimab with pemetrexed followed by cisplatin or carboplatin will be presented at an upcoming medical conference. GSK hints that the combination improves objective response compared with pembrolizumab and chemotherapy.

The first trial investigating a chimeric antigen receptor therapy to target GPRC5D in patients with resistant multiple myeloma reveals remissions in 70.6% of the enrolled patients.

Cary Gross, MD, discusses the background of his research on patients with lung cancer and Medicaid.

In an interview with Targeted Oncology, Naval G. Daver, MD, discussed the approved and investigational CD47 monoclonal antibodies for patients with acute myeloid leukemia and myelodysplastic syndrome and where research is taking this space.

Updated results from the L-MIND trial show continued efficacy and safety data for the combination of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.